Surgical Site Infections
Surgical Site Infections Market

Surgical Site Infections (SSI) are the most common nosocomial infection and frequently cause morbidity and mortality among inpatients of hospitals. Surgical Site Infection occurs after surgery in the part of the body where the surgery took place.


Surgical Site Infections Epidemiological Segmentation 


  • Total surgical procedures of Surgical Site Infections
  • Number of surgical procedures by type
  • Total incident cases of Surgical Site Infections
  • Incidence of Surgical Site Infections by type 


Surgical Site Infections Epidemiological Insights Observed in 2020


  • The total incident cases of Surgical Site Infections in the 7MM was 1,275,912.
  • The United States had the highest incident population of Surgical Site Infections.
  • Among the EU5 countries, the UK had the highest Incident population of Surgical Site Infections.
  • The lowest cases of Surgical Site Infections were found to be in Italy, with 61,942 cases.


Surgical Site Infections Market


The market size of Surgical Site Infections in the 7MM was found to be USD 418.79 million in 2020. 


Surgical Site Infections Emerging Drugs


The emerging drugs of the Surgical Site Infections market are


  • XF-73
  • D-PLEX100
  • Delafloxacin
  • BTX 1801
  • DFA-02
  • Zuragard, and others


Surgical Site Infections Key Players


The key players working in the Surgical Site Infections market are


  • Destiny Pharma 
  • PolyPid
  • Menarini Group Pharma
  • Botanix Pharma
  • Dr. Reddy's Laboratories Ltd.
  • Zurex Pharma, and others